Parent Education About Human Papillomavirus (HPV)

NCT07447245 | Recruiting DMC

• 1 other identifier: KTO Karatay Ünivesitesi
• Study Type: interventional
• Target: 52
• Locations: 1 country
• Sites: 1

Brief Summary

Human papillomavirus (HPV) is the most common sexually transmitted infection worldwide and is the primary cause of cervical cancer. According to World Health Organization (WHO) systems, there were approximately 660,000 new cases of cervical cancer and 350,000 deaths in 2022. In Turkey, the prevalence of cervical cancer was reported as 8,761 in the last five years. HPV vaccines are safe and effective in preventing HPV transmission and cancer and are included in 147 national immunization programs; However, they have not yet been included in the national immunization program in Turkey. The WHO has reissued a regional strategy to eliminate cervical cancer by 2030, which includes vaccinating 90% of girls by age 15, screening 70% of women between the ages of 35 and 45, and increasing the treatment of 90% of precancerous lesions and invasive cervical cancer. The HPV vaccine provides the highest protection before the onset of sexual activity, and ACIP recommends routine vaccination of all 11-12-year-olds (starting at age 9). Catch-up vaccination is recommended for individuals up to age 26 who have not been previously vaccinated. Gardasil and Cervarix vaccines have been licensed in Turkey since 2007; However, vaccination rates are limited by the vaccine not being covered by social security, its cost, the number of doses, and low parental awareness. The safety of HPV vaccines is regularly monitored by international organizations, with approximately 1.7 cases of anaphylaxis per million doses administered.

Conditions

HPV (Human Papillomavirus)-Associated

Keywords

HPV; vaccine; patern; education

Outcome Measures

Primary Outcomes (1)

• the human papillomavirus knowledge scale

  General HPV knowledge", with 16 questions on the subjects' general knowledge of HPV. The second subscale, "HPV testing knowledge", has six items related to HPV screening tests. The third subscale, "HPV vaccine knowledge" consists of seven items regarding HPV vaccine information. "HPV vaccine availability" items, the independent HPV-KS subscale, is organized in three different ways for the HPV vaccine program, which is conducted in three countries (the UK, the US, and Australia) where the scale is applied. The independent subscale can be modified to align with each country's HPV vaccine policy. Participants mark each item of the HPV-KS as "Yes", "No", and "I don't know". In the evaluation phase, each correct answer is scored as "1", and wrong answers and "I don't know" statements are scored as "0". The total HPV-KS score may be between "0 and 35". Higher scores indicate a thorough understanding of HPV general knowledge, HPV screening tests, and the HPV vaccine.

  Baseline and 4 weeks

Study Arms (2)

Parent group that will receive HPV training

EXPERIMENTAL

Parents in the experimental group will be asked to remain in the meeting room where they will receive information about HPV and the HPV vaccine, and an educational booklet will be distributed. After the training, they will be asked to answer questions 1, 13, 14, 15, and 16 of the sociodemographic characteristics form again, and the HPV-BÖ (HPV-Vaccine Test) will be administered again. One month later, the same group members will be asked to return to the institution, and they will be informed that invitations will be sent again. A reminder letter containing the date and time of their visit will be sent via their children three days before the measurement date. Parents who cannot attend will be contacted by phone if they wish, and questions 1, 13, 14, 15, and 16 of the sociodemographic characteristics form and the HPV-BÖ will be administered a third time to assess information retention and to inquire about vaccination inclination.

Behavioral: Education about vaccination

Control group to receive HPV training

NO INTERVENTION

Parents in the control group will be thanked for their participation in the study after completing the sociodemographic characteristics form and the HPV-BQ test, and will be informed that they will be asked to return to the institution in one month. A reminder letter (Appendix 7) containing the date and time of their return will be sent via their children three days prior to the measurement date. Parents returning to the institution will have questions 1, 13, 14, 15, and 16 of the sociodemographic characteristics form and the HPV-BQ test administered a second time, and the HPV education previously given to the experimental group will be repeated for the control group on their return date.

Interventions

Education about vaccination BEHAVIORAL

Parents of children eligible for the HPV vaccine will have their knowledge of HPV assessed and will receive education about the HPV vaccine. Following the education, the parents' knowledge levels and vaccination inclinations will be re-evaluated.

Parent group that will receive HPV training

Eligibility Criteria

• Age: 11 Years - 49 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• Parent must be between 18-49 years old
• Parent must be a child aged 11-18
• Parent must not have hearing or speech problems
• Parent must be able to read and write in Turkish
• Parent must agree to participate in the study

You may not qualify if:

• Parents of children who have received the HPV vaccine

Sponsors & Collaborators

• KTO Karatay University: lead

Study Sites (1)

Kto Karatay University

Konya, 42020, Turkey (Türkiye)

RECRUITING

MeSH Terms

Conditions

Papillomavirus Infections

Condition Hierarchy (Ancestors)

Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Communicable Diseases; Infections; DNA Virus Infections; Virus Diseases; Tumor Virus Infections; Genital Diseases; Urogenital Diseases; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Funda Gürbüz, Öğr. Gör

CONTACT

05065005321; funda.gurbuz@karatay.edu.tr

Emine GEÇKİL, Prof. Dr

CONTACT

eminegeckil@gmail.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: This study is a pre-test-post-test control group randomized controlled trial.

Study Record Dates

• First Submitted: December 6, 2025
• First Posted: March 3, 2026
• Study Start: February 15, 2026
• Primary Completion: June 15, 2026
• Study Completion (Estimated): December 15, 2026
• Last Updated: March 3, 2026

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)